- Home
- IMNN vs EVGN Comparison
IMNN vs EVGN Comparison
Compare IMNN & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- EVGN
- Stock Information
- Founded
- IMNN 1982
- EVGN 1999
- Country
- IMNN United States
- EVGN Israel
- Employees
- IMNN N/A
- EVGN N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- EVGN Agricultural Chemicals
- Sector
- IMNN Health Care
- EVGN Industrials
- Exchange
- IMNN Nasdaq
- EVGN Nasdaq
- Market Cap
- IMNN 12.1M
- EVGN 7.3M
- IPO Year
- IMNN 1985
- EVGN N/A
- Fundamental
- Price
- IMNN $0.79
- EVGN $1.28
- Analyst Decision
- IMNN Buy
- EVGN Strong Buy
- Analyst Count
- IMNN 2
- EVGN 1
- Target Price
- IMNN $14.00
- EVGN $3.50
- AVG Volume (30 Days)
- IMNN 3.9M
- EVGN 5.5M
- Earning Date
- IMNN 08-13-2025
- EVGN 08-21-2025
- Dividend Yield
- IMNN N/A
- EVGN N/A
- EPS Growth
- IMNN N/A
- EVGN N/A
- EPS
- IMNN N/A
- EVGN N/A
- Revenue
- IMNN N/A
- EVGN $6,765,000.00
- Revenue This Year
- IMNN N/A
- EVGN N/A
- Revenue Next Year
- IMNN N/A
- EVGN $113.18
- P/E Ratio
- IMNN N/A
- EVGN N/A
- Revenue Growth
- IMNN N/A
- EVGN N/A
- 52 Week Low
- IMNN $0.37
- EVGN $0.95
- 52 Week High
- IMNN $3.65
- EVGN $7.19
- Technical
- Relative Strength Index (RSI)
- IMNN 40.14
- EVGN 47.35
- Support Level
- IMNN $0.93
- EVGN $1.27
- Resistance Level
- IMNN $1.03
- EVGN $1.63
- Average True Range (ATR)
- IMNN 0.18
- EVGN 0.16
- MACD
- IMNN -0.10
- EVGN -0.03
- Stochastic Oscillator
- IMNN 1.39
- EVGN 0.87
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.